Olympus Launches Venture Capital Fund to Strengthen Leadership in Medical Technology | national news



TOKYO and CENTER VALLEY, Pennsylvania, November 11, 2021 / PRNewswire / – Olympus Corporation (Tokyo: 7733), a global leader in medical technology, announced the creation of Olympus Innovation Ventures to invest in pioneering startups with innovative technologies that improve clinical outcomes, reduce healthcare costs and improve quality of life patients.

Olympus Innovation Ventures, a wholly owned subsidiary of Olympus Corporation of the Americas, is a venture capital fund focused on startups poised to improve patient outcomes, radically advance disease detection and treatment, and transform the operating theater. The new fund expands Olympus’ strategy to strengthen endoscopy and pave the way for next-generation tools and procedures for minimally invasive surgery.

Olympus’s venture capital fund is stadium independent, prioritizing early stage and growing companies on a global scale with solutions in therapeutic areas including gastroenterology, respiratory tract and ‘urology. Olympus awarded $ 50 million for initial commitments and follow-on investments in portfolio companies. In addition to capital, Olympus will help its portfolio companies succeed by bringing its clinical and technical expertise, its access to healthcare professionals and hospitals, and its ability to launch and scale innovative solutions on the market. global market.

For more information, please visit https://olympusamerica.com/venture-capital. Olympus Innovation Ventures can be contacted at [email protected]

Olympus has been a leader in optical and medical innovation for over 100 years, introducing a mass-produced microscope for Japan in 1919 and the world’s first practical gastrocamera in 1950. Olympus tools helped revolutionize minimally invasive surgery and evolved to detect and treat disease. Yasuo Takeuchi, CEO of Olympus Corporation, said, “Our investment underscores our commitment to making people’s lives safer, healthier and more fulfilling. Our goal is for this fund to continue our history of innovation and support our long-term growth and transformation.

Touchdown Ventures, a company specializing in corporate venture capital, will participate in the management of the Olympus Innovation Ventures fund. Touchdown will work closely with senior Olympus executives in all aspects of the operation of the fund.

“We are excited about what Olympus can bring to entrepreneurs through the company’s technical strengths, industry relationships, wide distribution and deep subject matter expertise,” said Scott Lenet, co-founder and president of Touchdown Ventures. “The entire Olympus Innovation Ventures team strives to be the partner of choice for innovators and to create a competitive advantage for their startups.

Nacho Abia, COO of Olympus Corporation, said: “This effort is another way for Olympus to demonstrate its commitment to excellence and create tangible value for providers and patients. We believe that we will play a significant role in advancing the care of how to detect, monitor and treat ailments and diseases. “

About Olympus

Olympus is passionate about creating customer-centric solutions for the medicine, life sciences and industrial equipment industries. For more than 100 years, Olympus has worked to make people’s lives healthier, safer and more fulfilling by helping to detect, prevent and treat disease; advance scientific research; and ensure public safety. As a leading medical technology company, our medical business uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to ” improve clinical outcomes, reduce overall costs and improve patient quality of life and safety. Olympus’ medical portfolio includes endoscopes, laparoscopes and video imaging systems, as well as surgical energy devices, system integration solutions, medical services and a wide range of endotherapy instruments. for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.

About Touchdown Ventures

Touchdown Ventures partners with companies to manage their venture capital programs. Touchdown works closely with each company to achieve the financial and strategic benefits of venture capital investments. The company is a registered investment advisor and has offices in Los Angeles, Philadelphia and San Francisco. You can find more information about Touchdown at www.touchdownvc.com

Safe Harbor Declaration

This press release contains statements that reflect our views on our future performance and constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “outlook”, “Believe”, “anticipate”, “appear”, “can”, “should”, “should”, “intend”, “plan”, “estimate”, “expect”, “expect” “,”, “Search”, “, references to future periods. Our opinions on future performance involve risks and uncertainties that are difficult to predict and, therefore, our actual results may differ materially from the results discussed in our forward-looking statements. We caution you against relying on any of these forward-looking statements.

Our future performance may be affected by levels of residential repair and renovation activity and, to a lesser extent, by the construction of new homes, our ability to maintain our strong brands and reputation and to develop innovative products, our ability to maintain our competitive position in our industries, our dependence on key customers, the duration and severity of the ongoing COVID-19 pandemic, including its impact on national and international economic activity, confidence consumers, our production capabilities, our people and our supply chain; the cost and availability of materials and the imposition of tariffs, our reliance on third party suppliers, the risks associated with our international operations and global strategies, our ability to obtain the expected benefits from our strategic initiatives, our ability to successfully execute our acquisition strategy and integrate the businesses we have and can acquire, our ability to attract, develop and retain talented and diverse staff, the risks associated with our reliance on information systems and technology , and our ability to derive the expected benefits from our investments in new technologies. These and other factors are discussed in detail in our most recent Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. . Any forward-looking statement made by us speaks only as of the date on which it was made. Factors or events that could cause our actual results to vary may occur from time to time and we cannot predict all of them. Unless required by law, we do not undertake to publicly update forward-looking statements as a result of new information, future events or otherwise.

View original content to download multimedia: https://www.prnewswire.com/news-releases/olympus-launches-venture-capital-fund-to-strengthen-medtech-leadership-301422685.html



Leave A Reply

Your email address will not be published.